Covid-19

Testagem eficiente e direcionada de COVID-19 nas fronteiras via inteligência artificial.

1 Out, 2021 | 22:01h

Efficient and targeted COVID-19 border testing via reinforcement learning – Nature

Editorial: Greece used AI to curb COVID: what other nations can learn – Nature

Comentário: An algorithm may have helped slow the spread of COVID-19 in Greece – University of Southern California

Comentário no Twitter

A @Nature paper describes Eva, a learning system that led to targeted SARS-CoV-2 testing of travellers arriving in Greece. It identified nearly twice as many asymptomatic, infected people than would be expected for random testing or entry restrictions. https://t.co/Xogj5l4KCS pic.twitter.com/VT5HcXN3ic

— Nature Portfolio (@NaturePortfolio) September 22, 2021

Compreendendo a transição da COVID-19 para endemicidade.

1 Out, 2021 | 21:59h

Transition to endemicity: Understanding COVID-19 – Cell

Conteúdos relacionados:

COVID will likely shift from pandemic to endemic — but what does that mean?

Perspective | How Endemic COVID Becomes a Manageable Risk – “Businesses and schools must adapt, because the dual threat from the coronavirus and the flu will be too severe”.

Revisão | COVID-19 em idosos.

1 Out, 2021 | 21:58h

COVID-19 in older adults – Cleveland Clinic Journal of Medicine

Estudo randomizado | Combinação de anticorpos REGEN-COV reduz hospitalizações em pacientes ambulatoriais com Covid-19.

1 Out, 2021 | 20:28h

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 – New England Journal of Medicine

Estudo randomizado com mais de 30.000 pacientes mostrou que a vacina da AstraZeneca é segura e teve 74% de eficácia contra infecção sintomática por SARS-CoV-2.

1 Out, 2021 | 20:27h

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine – New England Journal of Medicine

Comentários no Twitter

In a phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants the incidence of serious adverse effects was low and the vaccine efficacy was 74%. Efficacy was documented in a range of demographic subgroups. #Covid19vaccine https://t.co/hK8q2dD6OT pic.twitter.com/58aXusCS4I

— NEJM (@NEJM) September 29, 2021

The pivotal trial of the Astra-Zeneca vaccine in over 32,000 participants, published today @NEJM.
Vaccine efficacy 74% [95% CI 65,80] vs symptomatic infections; maintained across subgroups,
age > 65: 84% [54,84] https://t.co/ou3nb15Khx pic.twitter.com/dlwRnrvyc0

— Eric Topol (@EricTopol) September 29, 2021

[Comunicado de imprensa – Ainda não publicado] Candidata da Clover a vacina contra COVID-19 demonstra 79% de eficácia contra a variante Delta.

1 Out, 2021 | 20:25h

Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest – Clover Biopharmaceutical

Comentário: New Chinese vaccine could bolster global arsenal – Science

Recapitulando a pandemia: lições que aprendemos.

1 Out, 2021 | 20:24h

A pandemic recap: lessons we have learned – World Journal of Emergency Surgery

Revisão | Características clínicas, laboratoriais e achados radiológicos de pacientes com mielopatia inflamatória aguda após infecção por COVID-19.

1 Out, 2021 | 20:23h

Clinical Features, Laboratory, and Radiological Findings of Patients With Acute Inflammatory Myelopathy After COVID-19 Infection: A Narrative Review – American Journal of Physical Medicine & Rehabilitation

Mais de um 1/3 dos pacientes com COVID-19 são posteriormente diagnosticados com pelo menos um sintoma de “long COVID”.

1 Out, 2021 | 20:22h

Comunicado de imprensa: Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom – University of Oxford

Estudo original: Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 – PLOS Medicine

Comentários:

Two studies tie long COVID-19 to severe initial illness – CIDRAP

Covid: 37% of people have symptoms six months after infection – The Guardian

Long Covid is a bigger problem than we thought – CNN

Expert reaction to study looking at incidence and co-occurrence of long COVID symptoms following COVID-19 infection and also after influenza – Science Media Centre

Revisão sistemática | Caracterização da “long COVID”.

1 Out, 2021 | 19:37h

Characterising long COVID: a living systematic review – BMJ Global Health

Conteúdos relacionados:

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (vários artigos sobre o tema)